Jun 30, 2026 08:01AM
Jun 30, 2026 08:00AM
Jun 15, 2026 04:30PM
Jun 9, 2026 08:31AM
Jun 9, 2026 08:30AM
May 12, 2026 07:30AM
May 12, 2026 07:30AM Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
May 8, 2026 07:30AM
May 8, 2026 07:30AM
Apr 22, 2026 08:30AM
Apr 22, 2026 08:30AM
Feb 12, 2026 04:30PM
Dec 17, 2025 08:30AM
Dec 17, 2025 08:30AM Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Nov 17, 2025 09:26AM
Nov 13, 2025 04:30PM
Nov 3, 2025 11:04AM
Nov 3, 2025 08:30AM
Oct 29, 2025 08:30AM
Oct 29, 2025 08:30AM
Oct 29, 2025 08:30AM Vistagen Appoints Paul Edick to its Board of Directors
Aug 7, 2025 04:30PM
Jun 25, 2025 08:36AM
Jun 25, 2025 08:30AM
Jun 17, 2025 04:30PM
Jun 2, 2025 08:31AM
Jun 2, 2025 08:30AM
Feb 13, 2025 04:30PM Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
Feb 5, 2025 08:32AM
Feb 5, 2025 08:30AM
Jan 10, 2025 08:30AM
Nov 7, 2024 04:20PM
Nov 5, 2024 08:30AM
Sep 23, 2024 08:31AM
Sep 23, 2024 08:30AM Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Aug 13, 2024 04:21PM
Jun 11, 2024 04:20PM
May 23, 2024 08:30AM
Apr 9, 2024 08:30AM
Apr 1, 2024 08:30AM
Apr 1, 2024 08:30AM
Feb 13, 2024 04:20PM Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
Dec 27, 2023 08:30AM
Dec 27, 2023 08:30AM
Dec 7, 2023 09:22AM
Dec 7, 2023 04:29AM
Dec 4, 2023 07:08AM
Nov 9, 2023 04:30PM
Aug 10, 2023 04:22PM VistaGen Therapeutics (VTGN) Reports Q1, Provides Corporate Update
Aug 10, 2023 04:21PM

325,855 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All